ESSA Pharma (NASDAQ:EPIX) Receives “Sell (E+)” Rating from Weiss Ratings

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI)‘s stock had its “sell (e+)” rating reiterated by Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

ESSA Pharma Price Performance

NASDAQ EPIX opened at $0.20 on Wednesday. The firm has a market cap of $9.52 million, a P/E ratio of -0.36 and a beta of 1.57. The stock’s 50-day moving average is $0.80 and its 200-day moving average is $1.39. ESSA Pharma has a one year low of $0.18 and a one year high of $6.45.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. Equities analysts anticipate that ESSA Pharma will post -0.42 EPS for the current year.

Hedge Funds Weigh In On ESSA Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd increased its stake in shares of ESSA Pharma by 84.7% in the 2nd quarter. XTX Topco Ltd now owns 42,173 shares of the company’s stock valued at $72,000 after purchasing an additional 19,344 shares during the last quarter. Deuterium Capital Management LLC bought a new stake in ESSA Pharma during the 1st quarter worth $174,000. Rangeley Capital LLC bought a new stake in ESSA Pharma during the 2nd quarter worth $289,000. DLD Asset Management LP bought a new stake in ESSA Pharma during the 1st quarter worth $290,000. Finally, JPMorgan Chase & Co. grew its position in ESSA Pharma by 14.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 189,094 shares of the company’s stock worth $321,000 after acquiring an additional 24,219 shares during the last quarter. 75.12% of the stock is owned by institutional investors and hedge funds.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.